JP2016501843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501843A5 JP2016501843A5 JP2015540216A JP2015540216A JP2016501843A5 JP 2016501843 A5 JP2016501843 A5 JP 2016501843A5 JP 2015540216 A JP2015540216 A JP 2015540216A JP 2015540216 A JP2015540216 A JP 2015540216A JP 2016501843 A5 JP2016501843 A5 JP 2016501843A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- lymphoma
- fragments
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001018034 Homo sapiens Lymphocyte antigen 75 Proteins 0.000 claims 25
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 claims 25
- 239000012634 fragment Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 229930126263 Maytansine Natural products 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
- 229930195731 calicheamicin Natural products 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 1
- 229960005501 duocarmycin Drugs 0.000 claims 1
- 229930184221 duocarmycin Natural products 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1220010.1 | 2012-11-07 | ||
| GBGB1220010.1A GB201220010D0 (en) | 2012-11-07 | 2012-11-07 | Therapeutic amd diagnostic target |
| PCT/GB2013/052899 WO2014072700A1 (en) | 2012-11-07 | 2013-11-06 | Ly75 as cancer therapeutic and diagnostic target |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018141190A Division JP7079685B2 (ja) | 2012-11-07 | 2018-07-27 | 癌治療および判断ターゲットとしてのｌｙ７５ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016501843A JP2016501843A (ja) | 2016-01-21 |
| JP2016501843A5 true JP2016501843A5 (cg-RX-API-DMAC7.html) | 2016-11-24 |
Family
ID=47429281
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540216A Pending JP2016501843A (ja) | 2012-11-07 | 2013-11-06 | 癌治療および判断ターゲットとしてのｌｙ７５ |
| JP2018141190A Active JP7079685B2 (ja) | 2012-11-07 | 2018-07-27 | 癌治療および判断ターゲットとしてのｌｙ７５ |
| JP2020154083A Pending JP2021011483A (ja) | 2012-11-07 | 2020-09-14 | 癌治療および判断ターゲットとしてのｌｙ７５ |
| JP2022177986A Active JP7479435B2 (ja) | 2012-11-07 | 2022-11-07 | 癌治療および判断ターゲットとしてのｌｙ７５ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018141190A Active JP7079685B2 (ja) | 2012-11-07 | 2018-07-27 | 癌治療および判断ターゲットとしてのｌｙ７５ |
| JP2020154083A Pending JP2021011483A (ja) | 2012-11-07 | 2020-09-14 | 癌治療および判断ターゲットとしてのｌｙ７５ |
| JP2022177986A Active JP7479435B2 (ja) | 2012-11-07 | 2022-11-07 | 癌治療および判断ターゲットとしてのｌｙ７５ |
Country Status (15)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201220010D0 (en) * | 2012-11-07 | 2012-12-19 | Oxford Biotherapeutics Ltd | Therapeutic amd diagnostic target |
| CU24320B1 (es) * | 2013-10-11 | 2018-02-08 | Berlin Chemie Ag | Anticuerpos conjugados contra antígeno linfocitario 75 para el tratamiento del cáncer |
| EP3303625B1 (en) | 2015-05-29 | 2019-03-27 | Universiteit Maastricht | Method for identifying subjects with aggressive melanoma skin cancer at diagnosis |
| KR101796091B1 (ko) | 2016-05-02 | 2017-11-10 | 충남대학교 산학협력단 | 카복실 말단 조절 단백질을 포함하는 두경부암 진단용 바이오 마커 조성물 |
| GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
| GB201809746D0 (en) * | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| CN109685135B (zh) * | 2018-12-21 | 2022-03-25 | 电子科技大学 | 一种基于改进型度量学习的少样本图像分类方法 |
| JP2023503615A (ja) * | 2019-11-26 | 2023-01-31 | シーダーズ－サイナイ メディカル センター | 循環からミトコンドリアｄｎａ又はゲノムｄｎａを枯渇させることにより疾患及び症状を治療する組成物及び方法 |
| WO2023032994A1 (ja) | 2021-08-31 | 2023-03-09 | 富士フイルム株式会社 | 化合物及びこれを用いた標識生体物質 |
| JPWO2023032996A1 (cg-RX-API-DMAC7.html) | 2021-08-31 | 2023-03-09 | ||
| WO2023032995A1 (ja) | 2021-08-31 | 2023-03-09 | 富士フイルム株式会社 | 化合物及びこれを用いた標識生体物質 |
| EP4401831A2 (en) * | 2021-09-13 | 2024-07-24 | Regeneron Pharmaceuticals, Inc. | Methods of treating clonal hematopoiesis of indeterminate potential (chip) with lymphocyte antigen 75 (ly75), cluster of differentiation 164 (cd164), or poly(adp-ribose) polymerase 1 (parp1) inhibitors |
| CN120380327A (zh) | 2022-12-26 | 2025-07-25 | 富士胶片株式会社 | 荧光强度增强剂、经荧光标记的靶标生物物质的荧光强度增强方法及荧光检测用试剂盒 |
| JPWO2024181454A1 (cg-RX-API-DMAC7.html) | 2023-02-27 | 2024-09-06 | ||
| JPWO2024181455A1 (cg-RX-API-DMAC7.html) | 2023-02-27 | 2024-09-06 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US20040258688A1 (en) * | 1995-01-31 | 2004-12-23 | Daniel Hawiger | Enhanced antigen delivery and modulation of the immune response therefrom |
| US6432666B1 (en) * | 1996-05-29 | 2002-08-13 | The Corporation Of The Trustees Of The Sisters Of Mercy In Queensland | Dendritic cell receptor |
| AU2002237972B2 (en) * | 2001-01-31 | 2007-11-29 | Biogen Idec Inc. | Use of CD23 antagonists for the treatment of neoplastic disorders |
| US20040146948A1 (en) * | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| WO2008104803A2 (en) * | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
| CN101801419A (zh) * | 2007-06-08 | 2010-08-11 | 米尔纳疗法公司 | 作为治疗干预的靶标的miR-34调控的基因和路径 |
| CA2704583A1 (en) * | 2007-11-07 | 2009-05-14 | Celldex Therapeutics Inc. | Antibodies that bind human dendritic and epithelial cell 205 receptor(dec-205) |
| EP2159291A1 (en) * | 2008-09-01 | 2010-03-03 | Agendia B.V. | Means and method for determining tumor cell percentage in a sample |
| CA2813494A1 (en) * | 2009-10-08 | 2011-04-14 | President And Fellows Of Harvard College | Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences |
| WO2012122396A1 (en) * | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| GB201220010D0 (en) * | 2012-11-07 | 2012-12-19 | Oxford Biotherapeutics Ltd | Therapeutic amd diagnostic target |
| JP6431104B2 (ja) * | 2017-02-27 | 2018-11-28 | オリコン株式会社 | マイクロ波を利用した金属蒸気の発生方法 |
-
2012
- 2012-11-07 GB GBGB1220010.1A patent/GB201220010D0/en not_active Ceased
-
2013
- 2013-06-11 UA UAA201504407A patent/UA117569C2/uk unknown
- 2013-11-06 SG SG10201810357WA patent/SG10201810357WA/en unknown
- 2013-11-06 HK HK16102576.0A patent/HK1214611A1/zh unknown
- 2013-11-06 BR BR112015009438-4A patent/BR112015009438B1/pt active IP Right Grant
- 2013-11-06 AU AU2013343277A patent/AU2013343277B2/en active Active
- 2013-11-06 KR KR1020157011701A patent/KR102256552B1/ko active Active
- 2013-11-06 EA EA201590694A patent/EA033649B1/ru unknown
- 2013-11-06 EP EP13789381.4A patent/EP2917239A1/en active Pending
- 2013-11-06 JP JP2015540216A patent/JP2016501843A/ja active Pending
- 2013-11-06 WO PCT/GB2013/052899 patent/WO2014072700A1/en not_active Ceased
- 2013-11-06 SG SG11201503363WA patent/SG11201503363WA/en unknown
- 2013-11-06 NZ NZ707116A patent/NZ707116A/en unknown
- 2013-11-06 CN CN202110466746.1A patent/CN113181372A/zh active Pending
- 2013-11-06 US US14/440,483 patent/US20150297743A1/en not_active Abandoned
- 2013-11-06 CN CN201380056271.2A patent/CN104755496A/zh active Pending
-
2015
- 2015-04-27 CL CL2015001098A patent/CL2015001098A1/es unknown
-
2018
- 2018-05-17 AU AU2018203478A patent/AU2018203478B2/en active Active
- 2018-07-27 JP JP2018141190A patent/JP7079685B2/ja active Active
-
2019
- 2019-04-24 US US16/392,796 patent/US20190317100A1/en not_active Abandoned
-
2020
- 2020-09-14 JP JP2020154083A patent/JP2021011483A/ja active Pending
- 2020-11-18 US US16/951,023 patent/US20210346512A1/en not_active Abandoned
-
2022
- 2022-11-07 JP JP2022177986A patent/JP7479435B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501843A5 (cg-RX-API-DMAC7.html) | ||
| NZ707116A (en) | Ly75 as cancer therapeutic and diagnostic target | |
| RU2017132214A (ru) | Анти-pvrig антитела и способы применения | |
| JP2016513094A5 (cg-RX-API-DMAC7.html) | ||
| CY1124634T1 (el) | Μορια προσδεσης pd-1 και lag-3 και μεθοδοι χρησης αυτων | |
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| JP2010518847A5 (cg-RX-API-DMAC7.html) | ||
| IL272572A (en) | Antibody compositions for tumor treatment | |
| Hayes et al. | Antitumor activity of an anti‐CD 98 antibody | |
| ZA201904431B (en) | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases | |
| UA90082C2 (ru) | Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25 | |
| JP2017501137A5 (cg-RX-API-DMAC7.html) | ||
| RU2014133069A (ru) | Транслокации r-спондина и способы с их использованием | |
| EP2210939A4 (en) | Anti-bst2 antibody | |
| JP2008538289A5 (cg-RX-API-DMAC7.html) | ||
| JP2014513068A5 (cg-RX-API-DMAC7.html) | ||
| JP2013506675A5 (cg-RX-API-DMAC7.html) | ||
| JP2009536834A5 (cg-RX-API-DMAC7.html) | ||
| RU2018125490A (ru) | Нейтрализация ингибиторных путей в лимфоцитах | |
| JP2013507968A5 (cg-RX-API-DMAC7.html) | ||
| RU2014140119A (ru) | Способы повышения эффективности терапии на основе cd37 | |
| JP2015514716A5 (cg-RX-API-DMAC7.html) | ||
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| US20150361504A1 (en) | Biomarker for predicting response of cll to treatment with a btk inhibitor | |
| JP2016502091A5 (cg-RX-API-DMAC7.html) |